Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
Baxter
Express Scripts

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

OXBRYTA Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Oxbryta, and what generic alternatives are available?

Oxbryta is a drug marketed by Global Blood Theraps and is included in one NDA. There are nine patents protecting this drug.

This drug has two hundred and eighteen patent family members in thirty-four countries.

The generic ingredient in OXBRYTA is voxelotor. Additional details are available on the voxelotor profile page.

DrugPatentWatch® Generic Entry Outlook for Oxbryta

Oxbryta will be eligible for patent challenges on November 25, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 12, 2037. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Free Forever Trial

Summary for OXBRYTA
International Patents:218
US Patents:9
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 38
Clinical Trials: 3
Patent Applications: 59
Drug Prices: Drug price information for OXBRYTA
What excipients (inactive ingredients) are in OXBRYTA?OXBRYTA excipients list
DailyMed Link:OXBRYTA at DailyMed
Drug patent expirations by year for OXBRYTA
Drug Prices for OXBRYTA

See drug prices for OXBRYTA

DrugPatentWatch® Estimated Generic Entry Opportunity Date for OXBRYTA
Generic Entry Date for OXBRYTA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OXBRYTA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Emory UniversityPhase 2
Global Blood TherapeuticsPhase 2
Global Blood TherapeuticsPhase 4

See all OXBRYTA clinical trials

US Patents and Regulatory Information for OXBRYTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Global Blood Theraps OXBRYTA voxelotor TABLET;ORAL 213137-001 Nov 25, 2019 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Global Blood Theraps OXBRYTA voxelotor TABLET;ORAL 213137-001 Nov 25, 2019 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Global Blood Theraps OXBRYTA voxelotor TABLET;ORAL 213137-001 Nov 25, 2019 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Global Blood Theraps OXBRYTA voxelotor TABLET;ORAL 213137-001 Nov 25, 2019 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Global Blood Theraps OXBRYTA voxelotor TABLET;ORAL 213137-001 Nov 25, 2019 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Merck
Dow
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.